Navigation Links
Reportlinker Adds Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile
Date:10/16/2009

NEW YORK, Oct. 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile

http://www.reportlinker.com/p0155101/Reportlinker-Adds-Chugai-Pharmaceutical-Co-Ltd-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Chugai's performance against key rivals in the prescription pharmaceutical sector

*Evaluate the impact of Chugai's alliance with Roche, including forecast strong growth for the Genentech-derived mAb portfolio in Japan

*Assess the forecast performance of Actemra, the first monoclonal antibody product to be developed and successfully launched by a Japanese company

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Financial performance, 2002-14 7

Chugai: PharmaVitae forecasts at a glance 8

Strategic insight 9

The Roche/Genentech/Chugai alliance 9

Partnership grants Chugai access to leading mAb portfolio 9

Reliance on mAb portfolio 9

Chugai dominates the Japanese mAb landscape 10

Roche/Genentech portfolio to contribute majority of Chugai's forecast growth 11

Chugai is good strategic fit for Roche's Japanese market expansion 13

SWOT analysis 14

Strengths 14

Weaknesses 15

Opportunities 16

Threats 16

Table of Contents 18

Table of figures 20

Chapter 3 Quarterly news update 21

Product developments 21

Deals and alliances 22

Product deals 22

Technology deals 22

M&A activity 23

Company announcements 23

Future product milestones 24

Chapter 4 Company introduction 25

Key findings 25

Background 26

Key corporate developments 26

M&A history 27

Acquisition of GenProbe in December 1989 27

Consolidation into the Roche group in October 2002 27

Divestments since the Roche merger have promoted Rx focus 28

Current corporate structure 29

Chapter 5 Company sales 30

Key findings 30

Prescription pharmaceutical sales and growth rate analysis, 2002-14 31

Product analysis 33

Product analysis, 2002-08 34

Product analysis, 2008-14 38

Therapy area analysis 42

Geographic analysis 45

Launch/core/expiry analysis 48

Explanation of launch/core/expiry analysis 48

Launch analysis, 2008-14 49

Core analysis, 2008-14 51

Expiry analysis, 2008-14 53

Launch/core/expiry configuration, 2008-14 54

Molecule type analysis 55

Externalization analysis 58

Chapter 6 Company financials 61

Key findings 61

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 62

Operating costs and profit analysis 64

Operating costs and profit analysis, 2002-08 65

Operating cost ratio and profit margin analysis, 2002-08 67

Operating cost ratio and profit margin analysis, 2008-14 68

Operating costs and profit analysis, 2008-14 69

Chapter 7 Key products and competitors 70

Key findings 70

Overview 71

Oncology 72

Avastin 72

Overview 72

Sales forecast 73

First-to-market VEGF inhibitor 73

Indication broadening expected to drive sales 73

Key competitors 73

Herceptin 75

Overview 75

Sales forecast 76

What is Herceptin? 76

Key competition from Tykerb in the long term 77

Rituxan 78

Overview 78

Sales forecast 79

What is Rituxan? 79

Indication-broadening to promote sustained sales expansion 79

Rituxan currently faces little competition and steady sales are anticipated 80

Neutrogin 81

Overview 81

Sales forecast 82

Internally developed Neutrogin is central to Chugai's historical growth 82

Biosimilar threat to EU market 83

Tarceva 84

Overview 84

Sales forecast 85

What is Tarceva? 85

Key competitors 85

Hematology 87

Epogin 87

Overview 87

Sales forecast 88

Kirin's Espo and follow-on Nesp pose key competition 88

Mircera to become Epogin's follow-on product 89

Safety concerns around EPO use in some cancer patients 89

Biosimilar EPOs available in the 5EU 89

R-744/Mircera 90

Overview 90

Sales forecast 91

R-744/Mircera provides follow-on to Epogin 91

Kirin's Nesp, a follow-on to Espo, will provide key competition 91

Immunology & inflammation 93

Actemra 93

Overview 93

Sales forecast 94

What is Actemra? 94

Key competitors 94

Product positioning 94

Infectious disease 96

Tamiflu 96

Overview 96

Sales forecast 97

Stockpiling represents majority of historical revenue 97

Pegasys 98

Overview 98

Sales forecast 99

The advantages of pegylation 99

Schering-Plough's Peg-Intron is the market leader in Japan 99

Copegus launch to facilitate growth over forecast period 100

Pipeline competitors present long-term threat 100

Genitourinary 102

Evista 102

Overview 102

Sales forecast 103

Evista is the only SERM osteoporosis treatment in Japan 103

Japanese guidelines rate Evista as a class A osteoporosis treatment 103

R484/Boniva and ED-71 launch will boost Chugai's osteoporosis franchise 103

Musculoskeletal 105

R-484/Boniva 105

Overview 105

Sales forecast 106

Chapter 8 Appendix 107

R&D pipeline 107

References 108

Datamonitor (2009), AstraZeneca plc: PharmaVitae Profile, March 2009, CSHC1408 108

Abbreviations 109

Exchange rates 110

About Datamonitor 111

About Datamonitor Healthcare 111

Datamonitor consulting 111

Disclaimer 113

List of Tables

Table 1: Chugai - PharmaVitae forecasts at a glance 8

Table 2: Chugai key product developments, 2009 21

Table 3: Chugai product deals and alliances, 2009 22

Table 4: Chugai technology deals and alliances, 2009 22

Table 5: Chugai M&A activity, 2009 23

Table 6: Chugai company announcements, 2009 23

Table 7: Chugai future product milestones, 2009-11 24

Table 8: Chugai product portfolio overview ($m), 2002-08 34

Table 9: Chugai product portfolio overview ($m), 2008-14 38

Table 10: Chugai prescription pharmaceutical sales by therapy area ($m), 2008-14 43

Table 11: Chugai prescription pharmaceutical sales by geographic region ($m), 2008-14 46

Table 12: Chugai launch portfolio overview ($m), 2008-14 49

Table 13: Chugai core portfolio overview ($m), 2008-14 51

Table 14: Chugai expiry portfolio overview ($m), 2008-14 53

Table 15: Chugai prescription pharmaceutical sales by molecule type ($m), 2008-14 56

Table 16: Chugai prescription pharmaceutical sales by source ($m), 2008-14 59

Table 17: Total Chugai sales by business unit ($m), 2002-08 62

Table 18: Chugai operating revenue/cost analysis ($m), 2002-08 65

Table 19: Chugai operating cost ratio analysis (% of total revenues), 2002-08 67

Table 20: Chugai operating cost ratio analysis (% of total revenues), 2008-14 68

Table 21: Chugai operating revenue/cost analysis ($m), 2008-14 69

Table 22: Key products overview 71

Table 23: Avastin: overview 72

Table 24: Avastin: sales forecast ($m), 2008-14 73

Table 25: Herceptin: overview 75

Table 26: Herceptin: sales forecast ($m), 2008-14 76

Table 27: Rituxan: overview 78

Table 28: Rituxan: sales forecast ($m), 2008-14 79

Table 29: Neutrogin: overview 81

Table 30: Neutrogin: sales forecast ($m), 2008-14 82

Table 31: Tarceva: overview 84

Table 32: Tarceva: sales forecast ($m), 2008-14 85

Table 33: Epogin: overview 87

Table 34: Epogin: sales forecast ($m), 2008-14 88

Table 35: R-744/Mircera: overview 90

Table 36: R-744/Mircera: sales forecast ($m), 2008-14 91

Table 37: Actemra: overview 93

Table 38: Actemra: sales forecast ($m), 2008-14 94

Table 39: Tamiflu: overview 96

Table 40: Tamiflu: sales forecast ($m), 2008-14 97

Table 41: Stockpiling and prescription Tamiflu sales ($m), 2003-08 97

Table 42: Pegasys: overview 98

Table 43: Pegasys: sales forecast ($m), 2008-14 99

Table 44: Evista: overview 102

Table 45: Evista: sales forecast ($m), 2008-14 103

Table 46: R-484/Boniva: overview 105

Table 47: R-484/Bomiva: sales forecast ($m), 2008-14 106

Table 48: Chugai's R&D pipeline (Phase I-registration) 107

Table 49: Exchange rates, 2009 110

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Chugai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Chugai's financial performance ($m), 2002-14 7

Figure 4: Roche/Genentech/Chugai alliance 9

Figure 5: Chugai dependency on mAb portfolio as a % of total revenues, 2002-14 10

Figure 6: Total Japanese mAb market sales by company, 2002-14 ($m) 11

Figure 7: Chugai pharmaceutical sales growth by source company, 2002-14 ($m) 12

Figure 8: Chugai SWOT analysis 14

Figure 9: Current corporate structure 29

Figure 10: Chugai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 31

Figure 11: Key product sales ($m), 2002-14 33

Figure 12: Chugai key sales growth drivers and resistors ($m), 2002-08 35

Figure 13: Chugai key sales growth drivers and resistors ($m), 2008-14 39

Figure 14: Chugai prescription pharmaceutical sales by therapy area ($m), 2002-14 42

Figure 15: Chugai prescription pharmaceutical sales by geographic region ($m), 2002-14 45

Figure 16: Chugai launch/core/expiry configuration ($m), 2008-14 54

Figure 17: Chugai prescription pharmaceutical sales by molecule type ($m), 2002-14 55

Figure 18: Chugai prescription pharmaceutical sales by source ($m), 2002-14 58

Figure 19: Chugai operating revenue/cost analysis ($m), 2002-14 64

To order this report:

Reportlinker Adds Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile

http://www.reportlinker.com/p0155101/Reportlinker-Adds-Chugai-Pharmaceutical-Co-Ltd-PharmaVitae-Profile.html

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 (Kanadische ... http://www.sedar.com ) und der Website ... --> http://www.sedar.com ) und ... abrufbar.    --> Telesta ... Konzernabschluss des zweiten Quartals und die ...
(Date:2/12/2016)... 2016  Sequent Medical, Inc. gab heute bekannt, ... eine Studie zur Sicherheit und Wirksamkeit des WEB™-Systems ... Behandlung von rupturierten intrakraniellen Aneurysmen begonnen hat. Prof. ... an der Universitätsklinik Bicètre in Paris ... den ersten Patienten aufgenommen. Im Rahmen ...
(Date:2/12/2016)... AUSTIN, Texas , Feb. 12, 2016 ... Institute for Robotic Surgery at St. David,s North Austin ... the da Vinci ® Xi ® Surgical ... ® 7000dV. Thiru Lakshman , M.D., ... performed a total proctocolectomy utilizing Integrated Table Motion technology, ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 12, 2016 , ... Erlanger Agency has announced a new partnership in its ... campaign focuses on the fight against breast cancer, fundraising for a local woman named ... . , Carmen is a loving single mother of two boys who also serves ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
(Date:2/12/2016)... ... ... For Coast Dental dentist Everet Lake, DDS, the smiles began at dawn. ... before 7 a.m. to volunteer at Friday’s Dentistry from the Heart event in New ... help hundreds of uninsured and underinsured people receive much-needed dental care. , This ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today announces the ... print component of “Revolutionizing Cancer Care” is distributed within the February 12 issue ... with a circulation of approximately 250,000 copies and an estimated readership of 750,000 ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Drug Categories: Strategies for Health Plans and PBMs,” an upcoming Feb. 24 webinar ... affordability and access in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C ...
Breaking Medicine News(10 mins):